BRPI0821683B8 - uso de um agonista parassimpático e de um antagonista simpático ou um agonista simpático para tratar presbiopia, miopia, hipermetropia, emetropia e/ou astigmatismo, e/ou para melhorar a visão noturna ou de baixa luz - Google Patents
uso de um agonista parassimpático e de um antagonista simpático ou um agonista simpático para tratar presbiopia, miopia, hipermetropia, emetropia e/ou astigmatismo, e/ou para melhorar a visão noturna ou de baixa luzInfo
- Publication number
- BRPI0821683B8 BRPI0821683B8 BRPI0821683A BRPI0821683A BRPI0821683B8 BR PI0821683 B8 BRPI0821683 B8 BR PI0821683B8 BR PI0821683 A BRPI0821683 A BR PI0821683A BR PI0821683 A BRPI0821683 A BR PI0821683A BR PI0821683 B8 BRPI0821683 B8 BR PI0821683B8
- Authority
- BR
- Brazil
- Prior art keywords
- agonist
- sympathetic
- farsightedness
- myopia
- astigmatism
- Prior art date
Links
- 239000000556 agonist Substances 0.000 title abstract 6
- 230000002889 sympathetic effect Effects 0.000 title abstract 6
- 239000005557 antagonist Substances 0.000 title abstract 3
- 230000001734 parasympathetic effect Effects 0.000 title abstract 3
- 201000009310 astigmatism Diseases 0.000 title abstract 2
- 230000004305 hyperopia Effects 0.000 title abstract 2
- 201000006318 hyperopia Diseases 0.000 title abstract 2
- 208000001491 myopia Diseases 0.000 title abstract 2
- 230000004379 myopia Effects 0.000 title abstract 2
- 201000010041 presbyopia Diseases 0.000 title abstract 2
- 230000036040 emmetropia Effects 0.000 title 1
- 230000004438 eyesight Effects 0.000 title 1
- 239000003814 drug Substances 0.000 abstract 4
- 239000013543 active substance Substances 0.000 abstract 3
- 239000000203 mixture Substances 0.000 abstract 2
- QCHFTSOMWOSFHM-WPRPVWTQSA-N (+)-Pilocarpine Chemical compound C1OC(=O)[C@@H](CC)[C@H]1CC1=CN=CN1C QCHFTSOMWOSFHM-WPRPVWTQSA-N 0.000 abstract 1
- XYLJNLCSTIOKRM-UHFFFAOYSA-N Alphagan Chemical compound C1=CC2=NC=CN=C2C(Br)=C1NC1=NCCN1 XYLJNLCSTIOKRM-UHFFFAOYSA-N 0.000 abstract 1
- QCHFTSOMWOSFHM-UHFFFAOYSA-N SJ000285536 Natural products C1OC(=O)C(CC)C1CC1=CN=CN1C QCHFTSOMWOSFHM-UHFFFAOYSA-N 0.000 abstract 1
- VRYMTAVOXVTQEF-UHFFFAOYSA-N acetic acid [4-[2-(dimethylamino)ethoxy]-2-methyl-5-propan-2-ylphenyl] ester Chemical compound CC(C)C1=CC(OC(C)=O)=C(C)C=C1OCCN(C)C VRYMTAVOXVTQEF-UHFFFAOYSA-N 0.000 abstract 1
- IEJXVRYNEISIKR-UHFFFAOYSA-N apraclonidine Chemical compound ClC1=CC(N)=CC(Cl)=C1NC1=NCCN1 IEJXVRYNEISIKR-UHFFFAOYSA-N 0.000 abstract 1
- 230000009286 beneficial effect Effects 0.000 abstract 1
- 229960003679 brimonidine Drugs 0.000 abstract 1
- RFWZESUMWJKKRN-UHFFFAOYSA-N dapiprazole Chemical compound CC1=CC=CC=C1N1CCN(CCC=2N3CCCCC3=NN=2)CC1 RFWZESUMWJKKRN-UHFFFAOYSA-N 0.000 abstract 1
- 229960002947 dapiprazole Drugs 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003885 eye ointment Substances 0.000 abstract 1
- 230000001771 impaired effect Effects 0.000 abstract 1
- 229940095437 iopidine Drugs 0.000 abstract 1
- 239000007788 liquid Substances 0.000 abstract 1
- 229960003509 moxisylyte Drugs 0.000 abstract 1
- 230000004297 night vision Effects 0.000 abstract 1
- 229960001416 pilocarpine Drugs 0.000 abstract 1
- 238000011200 topical administration Methods 0.000 abstract 1
- 230000004304 visual acuity Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Emergency Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
medicamento compreendendo um agonista parassimpatético e um antagonista simpatético ou um agonista simpatético. é descrito um medicamento para administração tópica no olho de um humano ou animal que compreende pelo menos dois agentes farmacologicamente ativos. um dos agentes ativos é um agonista parassimpatético, tal como pilocarpina, e o outro agente ativo é tanto um antagonista simpatético tal como dapiprazol quanto timoxamina, ou um agonista simpatético tais como brimonidina ou iopidina. o medicamento é preferivelmente na forma de uma composição líquida, tais como gotas, um gel ou unguento para olho, e pode compreender uma composição de liberação lenta. o medicamento age para aumentar a acuidade visual por um período de diversas horas, e pode ser benéfico nos casos de presbiopia, miopia, hipermetropia, astigmatismo e/ou visão noturna prejudicada.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0724558.2A GB0724558D0 (en) | 2007-12-15 | 2007-12-15 | Optical correction |
PCT/GB2008/004129 WO2009077736A2 (en) | 2007-12-15 | 2008-12-15 | Optical correction |
Publications (3)
Publication Number | Publication Date |
---|---|
BRPI0821683A2 BRPI0821683A2 (pt) | 2015-06-16 |
BRPI0821683B1 BRPI0821683B1 (pt) | 2019-11-05 |
BRPI0821683B8 true BRPI0821683B8 (pt) | 2021-05-25 |
Family
ID=39048209
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0821683A BRPI0821683B8 (pt) | 2007-12-15 | 2008-12-15 | uso de um agonista parassimpático e de um antagonista simpático ou um agonista simpático para tratar presbiopia, miopia, hipermetropia, emetropia e/ou astigmatismo, e/ou para melhorar a visão noturna ou de baixa luz |
Country Status (10)
Country | Link |
---|---|
US (4) | US20090156606A1 (pt) |
EP (3) | EP3505169B1 (pt) |
CN (1) | CN101969940A (pt) |
AU (1) | AU2008337350A1 (pt) |
BR (1) | BRPI0821683B8 (pt) |
CA (1) | CA2747095C (pt) |
ES (2) | ES2572750T3 (pt) |
GB (1) | GB0724558D0 (pt) |
WO (1) | WO2009077736A2 (pt) |
ZA (1) | ZA201005026B (pt) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0724558D0 (en) | 2007-12-15 | 2008-01-30 | Sharma Anant | Optical correction |
WO2010125416A1 (en) * | 2009-04-27 | 2010-11-04 | Raouf Rekik | Drug delivery to the anterior and posterior segments of the eye |
US8299079B2 (en) * | 2009-05-22 | 2012-10-30 | Kaufman Herbert E | Preparations and methods for ameliorating or reducing presbyopia |
US20100298335A1 (en) * | 2009-05-22 | 2010-11-25 | Kaufman Herbert E | Preparations and Methods for Ameliorating or Reducing Presbyopia |
RU2469734C2 (ru) * | 2010-09-02 | 2012-12-20 | Григорий Владимирович Пантелеев | Лечебное средство для лечения расстройств аккомодаций "stiak" |
AU2012311239B2 (en) * | 2011-09-20 | 2017-10-19 | Allergan, Inc. | Compositions and methods for treating presbyopia, mild hyperopia, and irregular astigmatism |
US10507245B2 (en) * | 2012-07-19 | 2019-12-17 | Luis Felipe Vejarano Restrepo | Ophthalmic formulation and method for ameliorating presbyopia |
US9968594B2 (en) | 2013-08-28 | 2018-05-15 | Presbyopia Therapies Llc | Compositions and methods for the treatment of presbyopia |
US9314427B2 (en) | 2013-08-28 | 2016-04-19 | Presbyopia Therapies Llc | Compositions and methods for the improvement of distance vision and the treatment of refractive errors of the eye |
US10307408B2 (en) | 2013-08-28 | 2019-06-04 | Presbyopia Therapies, LLC | Contact lens compositions and methods for the treatment of presbyopia |
US9844537B2 (en) | 2013-08-28 | 2017-12-19 | Presbyopia Therapies Llc | Compositions and methods for the treatment of presbyopia |
US11179327B2 (en) | 2013-08-28 | 2021-11-23 | Lenz Therapeutics, Inc. | Compositions and methods for the treatment of presbyopia |
US9089562B2 (en) | 2013-08-28 | 2015-07-28 | Presbyopia Therapies Llc | Compositions and methods for the treatment of presbyopia |
US10617763B2 (en) | 2013-08-28 | 2020-04-14 | Presbyopia Therapies, LLC | Compositions and methods for the treatment of presbyopia |
US9320709B2 (en) | 2013-08-28 | 2016-04-26 | Presbyopia Therapies Llc | Storage stable compositions and methods for the treatment of refractive errors of the eye |
US10064818B2 (en) | 2013-08-28 | 2018-09-04 | Presbyopia Therapies, LLC | Compositions and methods for the treatment of presbyopia |
US9833441B2 (en) | 2013-08-28 | 2017-12-05 | Presbyopia Therapies Llc | Compositions and methods for the treatment of presbyopia |
CA3031370A1 (en) | 2016-08-19 | 2018-02-22 | Orasis Pharmaceuticals Ltd. | Ophthalmic pharmaceutical compositions and uses relating thereto |
WO2018054489A1 (en) | 2016-09-23 | 2018-03-29 | Hallboeoek Finn | Pharmacological treatment of myopia |
TWI822690B (zh) * | 2017-07-20 | 2023-11-21 | 中國大陸商盛元醫藥廣州有限公司 | 用於治療近視之組合物及方法 |
RU2020119228A (ru) * | 2017-11-17 | 2021-12-20 | Целликс Био Прайвет Лимитед | Соединения, композиции и способы лечения нарушений со стороны органа зрения и заболеваний кожи |
SG11202004019SA (en) * | 2017-11-17 | 2020-05-28 | Cellix Bio Private Ltd | Compositions and methods for the treatment of eye disorders |
US10610518B2 (en) | 2018-04-24 | 2020-04-07 | Allergan, Inc. | Presbyopia treatments |
US11077053B2 (en) | 2018-08-21 | 2021-08-03 | Allergan, Inc. | Alpha-2-adrenergic receptor agonists for treatment of presbyopia, visual glare, visual starbursts, visual halos and night myopia |
CN113164451A (zh) * | 2018-10-15 | 2021-07-23 | 奥库菲尔制药股份有限公司 | 治疗青光眼的方法和组合物及相关病症 |
CA3116589A1 (en) * | 2018-10-26 | 2020-04-30 | Ocuphire Pharma, Inc. | Methods and compositions for treatment of presbyopia, mydriasis, and other ocular disorders |
US20200297720A1 (en) * | 2019-03-22 | 2020-09-24 | Baradaina LLC | Methods of Treating Eye Disorders |
US20200352938A1 (en) * | 2019-05-08 | 2020-11-12 | Harrow Ip, Llc | Pharmaceutical compositions for treating presbyopia and methods for fabricating thereof |
EP3980005A4 (en) * | 2019-06-10 | 2023-09-20 | Visus Therapeutics, Inc. | CARABACHOL BROMONIDINE FORMULATION TO IMPROVE ANTI-PREBSYOPIA EFFECT |
JP2022536662A (ja) * | 2019-06-10 | 2022-08-18 | ヴィーサス セラピューティクス インコーポレイテッド | 多焦点性を作り出すために偽水晶体患者において副交感神経刺激薬を単独でまたは1種類もしくは複数種類のαアゴニストと組み合わせて使用する方法 |
MX2020012116A (es) * | 2020-11-12 | 2022-08-09 | Cesar Alejandro Sanchez Galeana | Composicion oftalmologica sinergica en dosis de baja concentracion eficaz en la prevencion, control y erradicacion de la presbicia. |
CN117529316A (zh) * | 2021-04-23 | 2024-02-06 | 奥库菲尔制药股份有限公司 | 用于治疗瞳孔散大、青光眼和其他眼部病症的方法和组合物 |
CN115368310A (zh) | 2021-05-18 | 2022-11-22 | 奥库菲尔医药公司 | 合成甲磺酸酚妥拉明的方法 |
US11648247B1 (en) | 2021-12-16 | 2023-05-16 | Lenz Therapeutics, Inc. | Compositions and methods for the treatment of presbyopia |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3883225A (en) * | 1972-11-06 | 1975-05-13 | Donald S Rehm | Methods and apparatus for treating acquired myopia and similar or related eye conditions |
US4136177A (en) * | 1977-01-31 | 1979-01-23 | American Home Products Corp. | Xanthan gum therapeutic compositions |
US5360801A (en) * | 1989-06-21 | 1994-11-01 | The Trustees Of The University Of Pennsylvania | Pharmacological stimulation of eye growth |
JPH07508751A (ja) * | 1992-07-02 | 1995-09-28 | テラー・オフサルミック・ファーマシューティカルズ・インコーポレーテッド | 老視治療のための方法および生産品 |
EP1050308A4 (en) * | 1998-01-28 | 2002-09-04 | Senju Pharma Co | PROPHYLACTIC MEASURES OR REMEDIES AGAINST VISION DISORDERS |
US6291466B1 (en) * | 1998-07-30 | 2001-09-18 | Allergan Sales, Inc. | Cholinergic agents in the treatment of presbyopia |
US6277855B1 (en) * | 2000-04-21 | 2001-08-21 | Inspire Pharmaceuticals, Inc. | Method of treating dry eye disease with nicotinic acetylcholine receptor agonists |
US20040116524A1 (en) * | 2002-02-04 | 2004-06-17 | Cohen Ben Z. | Method of administering opthalmic fluids |
US20060177430A1 (en) * | 2002-12-20 | 2006-08-10 | Chakshu Research Inc | Treatment of ocular disorders with ophthalmic formulations containing methylsulfonylmethane as a transport enhancer |
CN100558360C (zh) * | 2003-11-20 | 2009-11-11 | 奥特拉控股公司 | 羟胺组合物在制备缓解黄斑变性和其他眼科疾病的药物中的用途 |
MXPA03011987A (es) * | 2003-12-19 | 2005-06-23 | Osio Sancho Alberto | Metodo para el tratamiento de la presbicia induciendo cambios en el poder y fisiologia corneal. |
US7479277B2 (en) * | 2005-02-24 | 2009-01-20 | Wisconsin Alumni Research Foundation | Method for reducing intraocular pressure using integrin-linked kinase inhibitor |
US7931909B2 (en) * | 2005-05-10 | 2011-04-26 | Allergan, Inc. | Ocular therapy using alpha-2 adrenergic receptor compounds having enhanced anterior clearance rates |
PT1938839E (pt) | 2006-12-18 | 2009-09-30 | Jorge Luis Benozzi | Composições oftálmicas de estimulantes parassimpáticos e anti-inflamatórios para utilização no tratamento de presbiopia |
EP2097044A4 (en) | 2006-12-26 | 2012-10-10 | Quadra Logic Tech Inc | DRUG RELIEF IMPLANTS FOR INHIBITING OPTICAL DEFECTS |
GB0724558D0 (en) | 2007-12-15 | 2008-01-30 | Sharma Anant | Optical correction |
US20100298335A1 (en) * | 2009-05-22 | 2010-11-25 | Kaufman Herbert E | Preparations and Methods for Ameliorating or Reducing Presbyopia |
US8299079B2 (en) * | 2009-05-22 | 2012-10-30 | Kaufman Herbert E | Preparations and methods for ameliorating or reducing presbyopia |
-
2007
- 2007-12-15 GB GBGB0724558.2A patent/GB0724558D0/en not_active Ceased
-
2008
- 2008-12-15 AU AU2008337350A patent/AU2008337350A1/en not_active Abandoned
- 2008-12-15 WO PCT/GB2008/004129 patent/WO2009077736A2/en active Application Filing
- 2008-12-15 CN CN2008801268956A patent/CN101969940A/zh active Pending
- 2008-12-15 EP EP19000065.3A patent/EP3505169B1/en active Active
- 2008-12-15 EP EP08861490.4A patent/EP2242487B1/en not_active Not-in-force
- 2008-12-15 ES ES08861490.4T patent/ES2572750T3/es active Active
- 2008-12-15 CA CA2747095A patent/CA2747095C/en not_active Expired - Fee Related
- 2008-12-15 EP EP16000001.4A patent/EP3031457B1/en active Active
- 2008-12-15 ES ES16000001T patent/ES2725002T3/es active Active
- 2008-12-15 BR BRPI0821683A patent/BRPI0821683B8/pt active IP Right Grant
- 2008-12-15 US US12/334,916 patent/US20090156606A1/en not_active Abandoned
-
2010
- 2010-07-15 ZA ZA2010/05026A patent/ZA201005026B/en unknown
-
2012
- 2012-12-03 US US13/692,257 patent/US8829037B2/en active Active
-
2014
- 2014-09-08 US US14/479,852 patent/US9623007B2/en active Active
-
2017
- 2017-04-18 US US15/489,950 patent/US11278545B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
WO2009077736A2 (en) | 2009-06-25 |
CA2747095C (en) | 2020-02-18 |
US20170216281A1 (en) | 2017-08-03 |
EP3505169B1 (en) | 2021-11-03 |
EP3031457B1 (en) | 2019-02-06 |
BRPI0821683A2 (pt) | 2015-06-16 |
EP3031457A1 (en) | 2016-06-15 |
AU2008337350A1 (en) | 2009-06-25 |
US9623007B2 (en) | 2017-04-18 |
US8829037B2 (en) | 2014-09-09 |
EP3505169A1 (en) | 2019-07-03 |
US20130096131A1 (en) | 2013-04-18 |
CN101969940A (zh) | 2011-02-09 |
ES2572750T3 (es) | 2016-06-02 |
US20140378519A1 (en) | 2014-12-25 |
US11278545B2 (en) | 2022-03-22 |
US20090156606A1 (en) | 2009-06-18 |
CA2747095A1 (en) | 2009-06-25 |
ZA201005026B (en) | 2011-03-30 |
EP2242487B1 (en) | 2016-02-24 |
EP2242487A2 (en) | 2010-10-27 |
WO2009077736A4 (en) | 2010-02-25 |
GB0724558D0 (en) | 2008-01-30 |
ES2725002T3 (es) | 2019-09-18 |
BRPI0821683B1 (pt) | 2019-11-05 |
WO2009077736A3 (en) | 2009-12-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0821683B8 (pt) | uso de um agonista parassimpático e de um antagonista simpático ou um agonista simpático para tratar presbiopia, miopia, hipermetropia, emetropia e/ou astigmatismo, e/ou para melhorar a visão noturna ou de baixa luz | |
Benozzi et al. | Presbyopia: a new potential pharmacological treatment | |
AR121843A2 (es) | Formulación oftálmica y método para mejorar la presbicia | |
BR112012018500A2 (pt) | alguns inibidores de quinurenina-3-monooxigenase, composições farmacêuticas e métodos de uso destas | |
WO2012136969A3 (en) | Ophthalmic treatments | |
BR112014008789A2 (pt) | prevenção e tratamento de condições oculares | |
EA202091999A3 (ru) | Применение ингибиторов dpp iv | |
MX2014002459A (es) | Inhibidores de quinurenina-3-monooxigenasa, composiciones farmaceuticas y metodos de uso de los mismos. | |
WO2008154368A3 (en) | Topical poloxamer formulations for enhancing microvascular flow: compositions and uses thereof | |
AR084932A1 (es) | Composicion oftalmica que comprende un androgeno y su uso para la fabricacion de un medicamento util para el tratamiento de una enfermedad ocular resultante de una deficiencia androgenica | |
AU2012286851A8 (en) | Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
AR085662A1 (es) | Metodos y composiciones para tratar la hiperuricemia y trastornos metabolicos asociados con la hiperuricemia | |
PH12017502049A1 (en) | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
AR054249A1 (es) | Tratamiento de enfermedades del tejido conectivo de la piel | |
US20190374491A1 (en) | Topical preparation for pain relief | |
JP2021107464A (ja) | 眼科組成物 | |
EA201291335A1 (ru) | Фармацевтические композиции для местного применения | |
JP2024012412A (ja) | 局所と局部の麻酔と鎮痛 | |
EA201591653A1 (ru) | Композиции для лечения глазных расстройств с применением дипиридамола | |
CL2020001426A1 (es) | Composición tópica oftálmica que comprende ácido dobesilico para tratar enfermedades del segmento posterior del ojo. | |
US9187468B2 (en) | Topical ocular analgesic agents | |
AR074246A1 (es) | Derivados de 1-amino-alquilciclohexano para el tratamiento de trastornos del sueno | |
WO2014047288A3 (en) | Transglutaminase tg2 inhibitors, pharmaceutical compositions, and methods of use thereof | |
CA3126226A1 (en) | Aceclofenac and betamethasone synergic pharmaceutical composition for the treatment of pain caused by rheumatic diseases or post-surgical pain | |
BRPI0920492A2 (pt) | uso de deferiprona para o tratamento e prevenção de doenças oftalmológicas relacionadas ao ferro. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 05/11/2019, OBSERVADAS AS CONDICOES LEGAIS. |
|
B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 15/12/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |